ଟିଜାନିଡିନ

ଟିଜାନିଡିନ
Clinical data
Pronunciation	/taɪˈzænɪdiːn/ tye-ZAN-i-deen
Trade names	Zanaflex, Sirdalud, and others
Synonyms	4-Chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-8-thia-7,9-diazabicyclo[4.3.0]nona-2,4,6,9-tetraen-5-amine
AHFS/Drugs.com	monograph
MedlinePlus	a601121
Pregnancy; category	C;
Routes of; administration	By mouth (tablets, capsules)
Legal status
Legal status	UK: POM (Prescription only) ; US: ℞-only ;
Pharmacokinetic data
Bioavailability	~40%
Protein binding	~30%
Metabolism	Liver (CYP1A2, 95%)
Elimination half-life	2.54 hours (tizanidine), 20–40 hours (inactive metabolites)
Excretion	Urine (60%), feces (20%)
Identifiers
	IUPAC name 5-Chloro-N-(4,5-dihydro-1H-imidazol-2-yl)benzo[c] [1,2,5]thiadiazol-4-amine;
ECHA InfoCard	100.125.400
Chemical and physical data
Formula	C9H8ClN5S
Molar mass	୨୫୩.୭୧ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Clc1ccc3nsnc3c1NC/2=N/CCN\2;
	InChI InChI=1S/C9H8ClN5S/c10-5-1-2-6-8(15-16-14-6)7(5)13-9-11-3-4-12-9/h1-2H,3-4H2,(H2,11,12,13) ; Key:XFYDIVBRZNQMJC-UHFFFAOYSA-N ;
(verify)

ଟିଜାନିଡିନ (ଇଂରାଜୀ ଭାଷାରେ Tizanidine) ଏକ ଔଷଧ ଯାହା ମାଂସପେଶୀ କାଠିନ୍ୟ, ମେରୁଦଣ୍ଡ ଆଘାତ ବା ମଲ୍ଟିପ୍ଲ ସ୍କ୍ଲେରୋସିସ ଭଳି ଅବସ୍ଥର ଚିକିତ୍ସାରେ ଦିଆଯାଏ ଓ ଯାହାର ବ୍ୟବସାୟୀକ ନାମ ଜାନାଫ୍ଲେକ୍ସ (Zanaflex) ଅଟେ । ^[୨] ଏହା ବାକ୍ଲୋଫେନ ବା ଡାଏଜେପାମ ଭଳି କାମ କରେ | ^[୩] ଏହା ପାଟି ବାଟେ ଦିଆଯାଏ | ^[୪]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଶୁଖିଲା ପାଟି, ନିଦ୍ରାଳୁ ଭାବ, ଦୁର୍ବଳତା ଏବଂ ମୁଣ୍ଡ ବୁଲେଇବା ସମସ୍ୟା ହୁଏ | ^[୫] ଗୁରୁତର ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ନିମ୍ନ ରକ୍ତଚାପ, ଯକୃତ ସମସ୍ୟା, ସାଇକୋସିସ, ଓ ଦୀର୍ଘ କ୍ୟୁଟି ହୁଏ । ^[୫] ଗର୍ଭାବସ୍ଥାରେ ଏବଂ ସ୍ତନ୍ୟପାନରେ ଏହାର ନିରାପତ୍ତା ଅସ୍ପଷ୍ଟ ରହିଛି। ^[୬] ଏହା ଏକ ଆଲଫା ୨ ଆଡ୍ରେନର୍ଜିକ ଆଣ୍ଟାଗୋନିଷ୍ଟ ଔଷଧ ଓ ଏହାର କାର୍ଯ୍ୟବିଧି ଅସ୍ପଷ୍ଟ ଅଛି | ^[୫]

ଟିଜାନିଡିନ ୧୯୯୬ ମସିହାରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଚିକିତ୍ସା ନିମନ୍ତେ ଅନୁମୋଦିତ ହୋଇଥିଲା। ^[୫] ଏହା ଏକ ଜେନେରିକ ଔଷଧ ଭାବରେ ଉପଲବ୍ଧ। ^[୭] ଯୁକ୍ତରାଜ୍ୟରେ ୨୦୧୯ ସୁଦ୍ଧା ଏକ ମାସର ଯୋଗାଣ ମୂଲ୍ୟ ୩.୪୫ ପାଉଣ୍ଡ ଥିଲା । ^[୭] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ପରିମାଣର ହୋଲସେଲ ମୂଲ୍ୟ ପ୍ରାୟ ୪.୨୦ ଆମେରିକୀୟ ଡଲାର ଅଟେ। ^[୮] ୨୦୧୭ରେ ଏହା ୮୯ତମ ଅଧିକ ପ୍ରେସକ୍ରିପସନ ଔଷଧ ଥିଲା ଓ ୯ ନିୟୁତରୁ ଅଧିକ ଏହାର ପ୍ରେସକ୍ରିପସନ ହୋଇଥିଲା | ^[୯] ^[୧୦]

ଅଧାର

↑ ^୧.୦ ^୧.୧ "Zanaflex (tizanidine hydrochloride) Capsules and Tablets for Oral Use. Full Prescribing Information" (PDF). Acorda Therapeutics Inc. Ardsley, NY 10502. Archived from the original (PDF) on 22 March 2015. Retrieved 1 September 2016.
↑ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 1094. ISBN 9780857113382.
↑ Kamen L, Henney HR, Runyan JD (February 2008). "A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury". Current Medical Research and Opinion. 24 (2): 425–39. doi:10.1185/030079908X261113. PMID 18167175.
↑ "Tizanidine Hydrochloride Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). American Society of Health-System Pharmacists. Retrieved 3 March 2019.
↑ ^୫.୦ ^୫.୧ ^୫.୨ ^୫.୩ "Tizanidine Hydrochloride Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). American Society of Health-System Pharmacists. Retrieved 3 March 2019.
↑ "Tizanidine Pregnancy and Breastfeeding Warnings". Drugs.com (in ଇଂରାଜୀ). Retrieved 3 March 2019.
↑ ^୭.୦ ^୭.୧ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 1094. ISBN 9780857113382.
↑ "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services (in ଇଂରାଜୀ). Archived from the original on 2019-03-06. Retrieved 3 March 2019.
↑ "The Top 300 of 2020". ClinCalc. Retrieved 11 April 2020.
↑ "Tizanidine - Drug Usage Statistics". ClinCalc. Retrieved 11 April 2020.

[Zanaflex_PI-1] ୧.୦ ^୧.୧ "Zanaflex (tizanidine hydrochloride) Capsules and Tablets for Oral Use. Full Prescribing Information" (PDF). Acorda Therapeutics Inc. Ardsley, NY 10502. Archived from the original (PDF) on 22 March 2015. Retrieved 1 September 2016.

[BNF76-2] British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 1094. ISBN 9780857113382.

[Kam2008-3] Kamen L, Henney HR, Runyan JD (February 2008). "A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury". Current Medical Research and Opinion. 24 (2): 425–39. doi:10.1185/030079908X261113. PMID 18167175.

[AHFS2019-4] "Tizanidine Hydrochloride Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). American Society of Health-System Pharmacists. Retrieved 3 March 2019.

[autogen1-5] ୫.୦ ^୫.୧ ^୫.୨ ^୫.୩ "Tizanidine Hydrochloride Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). American Society of Health-System Pharmacists. Retrieved 3 March 2019.

[Preg2019-6] "Tizanidine Pregnancy and Breastfeeding Warnings". Drugs.com (in ଇଂରାଜୀ). Retrieved 3 March 2019.

[autogen2-7] ୭.୦ ^୭.୧ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 1094. ISBN 9780857113382.

[NADAC2019-8] "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services (in ଇଂରାଜୀ). Archived from the original on 2019-03-06. Retrieved 3 March 2019.

[ref-9] "The Top 300 of 2020". ClinCalc. Retrieved 11 April 2020.

[ref1-10] "Tizanidine - Drug Usage Statistics". ClinCalc. Retrieved 11 April 2020.

[୨]

[୩]

[୪]

[୧]

[୫]

[୬]

[୭]

[୮]

[୯]

[୧୦]

Clinical data


Pronunciation	/taɪˈzænɪdiːn/ tye-ZAN-i-deen
Trade names	Zanaflex, Sirdalud, and others
Synonyms	4-Chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-8-thia-7,9-diazabicyclo[4.3.0]nona-2,4,6,9-tetraen-5-amine
AHFS/Drugs.com	monograph
MedlinePlus	a601121
Pregnancy category	C
Routes of administration	By mouth (tablets, capsules)
Legal status
Legal status	UK: POM (Prescription only) US: ℞-only
Pharmacokinetic data
Bioavailability	~40%^[୧]
Protein binding	~30%
Metabolism	Liver (CYP1A2, 95%)
Elimination half-life	2.54 hours (tizanidine), 20–40 hours (inactive metabolites)^[୧]
Excretion	Urine (60%), feces (20%)
Identifiers
IUPAC name 5-Chloro-N-(4,5-dihydro-1H-imidazol-2-yl)benzo[c] [1,2,5]thiadiazol-4-amine
ECHA InfoCard	100.125.400
Chemical and physical data
Formula	C₉H₈ClN₅S
Molar mass	୨୫୩.୭୧ g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES Clc1ccc3nsnc3c1NC/2=N/CCN\2
InChI InChI=1S/C9H8ClN5S/c10-5-1-2-6-8(15-16-14-6)7(5)13-9-11-3-4-12-9/h1-2H,3-4H2,(H2,11,12,13)^Y Key:XFYDIVBRZNQMJC-UHFFFAOYSA-N^Y
(verify)